检索结果-南通市图书馆

Feasibility of cabazitaxel in octogenarian prostate cancer patients

Current Urology 2023年第3期17卷 153-158页

作者： paolo Tralongo Sebastiano Bordonaro Giuseppe Di Lorenzo Ugo De Giorgi NicolòBorsellino Gaetano Facchini Sabrina Rossetti Giuseppe Fornarini Vito Longo Antonino Carmelo Tralongo Francesca Caspani Massimiliano Spada Nicola Calvani paolo carlini Medical Oncology Unit RAO-Umberto I HospitalSiracusa96100Italy Department of Medicine and Health Sciences‘Vincenzo Tiberio' University of MoliseCampobassoItaly Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori(IRST)IRCCS Meldola(FC)Italy Medical Oncology Unit Ospedale Buccheri La FerlaFatebenefratelliPalermoItaly Medical Oncology Unit Santa Maria delle Grazie di PozzuoliNapoliItaly Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology Istituto Nazionale TumoriIRCCSFondazione G.PascaleNapoliItaly Medical Oncology 1 IRCCSOspedale Policlinico San MartinoGenovaItaly Istituto Tumori Giovanni paoloⅡI.R.C.C.S. BaOspedale di CircoloVareseItaly Medical Oncology Unit ASSTSETTE LAGHIOspedale di CircoloVareseItaly Medical Oncology Unit Fondazione Istituto G.Giglio di CefalùPalermoItaly Medical Oncology Division&Breast Unit Sen.A.Perrino HospitalBrindisiItaly Medical Oncology 1 Istituto Nazionale Tumori Regina ElenaRomaItaly

Background:To evaluate the effectiveness and safety of cabazitaxel in castration-resistant prostate cancer patients aged>80 years,we performed a retrospective study on a sample of patients from 11 Italian cancer *** and methods:Fifty-seven patients aged>80 years were treated with cabazitaxel after previous failure with docetaxel;39 completed a comprehensive geriatric assessment questionnaire(34 fit and 5 vulnerable)and 8 patients(14%)had an Eastern Cooperative Oncology Group performance status(PS)>2,while most had a PS of 0-1(86%).Cabazitaxel was administered at a dose of 25 mg/m^(2)in 30(52%)patients and 20 mg/m^(2)or adapted schedules in 27(48%)*** schedules were adopted mainly in patients>85 years(75%),with a PS>2(87.5%),and those classified as vulnerable(100%).Results:The duration of treatment was 4.8 months and was comparable in all subgroups;disease control rate was reported in 36 patients(63%);prostate-specific antigen response was recorded in 18 patients(31.5%).Median overall survival was 13.1 months regardless of age(85 years),but overall survival was reduced in vulnerable(7.2 months)and PS>2 patients(6.8 months).The most frequently documented grade 3-4 toxicities were neutropenia(14%)and diarrhea(10.5%).Six patients(10.5%)dropped out due to severe ***:Octogenarian patients can be treated with cabazitaxel with reduced doses or alternative schedules that are associated with less toxicity and fewer treatment *** geriatric assessment could facilitate more appropriate patient selection.

关键词： Cabazitaxel Cancer Octogenarian Prostate

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：